Adverum Biotechnologies Inc represents a strong set of values and corporate philosophy. The company is committed to advancing gene therapy through innovation and dedication. Adverum strives to deliver transformative gene therapies for patients with serious ocular diseases. With a collaborative and driven approach, Adverum aims to develop cutting-edge treatments that address unmet medical needs. By leveraging their expertise in gene therapy and a patient-centered mindset, Adverum focuses on improving the lives of individuals affected by genetic diseases. With a robust pipeline and a commitment to scientific excellence, the company is dedicated to making a positive impact in the field of biotechnology.

Adverum Biotechnologies Inc is primarily present in the United States.

Adverum Biotechnologies Inc has achieved several significant milestones since its establishment. The company successfully completed its Phase 1 clinical trial for ADVM-043, a treatment for hereditary angioedema. Additionally, Adverum Biotechnologies Inc received the FDA's Fast Track designation for ADVM-022, its ocular gene therapy candidate for wet age-related macular degeneration. The company also announced positive interim data from Phase 2 clinical trials of ADVM-022 in patients with wet AMD, demonstrating promising results and safety profile. Furthermore, Adverum Biotechnologies Inc expanded its manufacturing capabilities by establishing a new facility for in-house clinical and commercial production.

Adverum Biotechnologies Inc is a renowned biotechnology company with a rich history and background. Founded in 2006, the company focuses on developing gene therapies to treat serious ocular and rare diseases. Adverum leverages its advanced proprietary vector platform, known as ADVM, to deliver sustainable and long-term therapeutic benefits. With a strong commitment to innovation, Adverum continues to advance its pipeline of gene therapy candidates, aiming to address unmet medical needs globally. As a leader in biotech, Adverum Biotechnologies Inc strives to revolutionize treatment options and improve patients' lives through groundbreaking research and development efforts.

The main competitors of Adverum Biotechnologies Inc in the market include companies such as Spark Therapeutics, Applied Genetic Technologies Corporation, and Regenxbio Inc. These companies are also engaged in the development and commercialization of gene therapies, just like Adverum Biotechnologies Inc. Adverum Biotechnologies Inc competes with these companies in areas such as product development, scientific research advancements, and market penetration. By focusing on innovation, strategic partnerships, and delivering effective therapies, Adverum Biotechnologies Inc aims to differentiate itself from its competitors and establish a strong presence in the gene therapy market.

Adverum Biotechnologies Inc is primarily active in the biotechnology industry.

The business model of Adverum Biotechnologies Inc revolves around developing and commercializing gene therapy products for serious ocular and rare diseases. They utilize their innovative and proprietary adeno-associated virus (AAV) vector technology platform to deliver potentially transformative gene therapies. Adverum aims to improve the lives of patients by addressing the underlying cause of diseases through one-time treatments. With a focus on creating long-lasting effects, they target genetic diseases that affect the retina or diseases caused by the deficiency of a single gene. Adverum Biotechnologies Inc strives to advance gene therapy as a transformative medical approach by leveraging their expertise and innovative research.

Adverum Biotechnologies hissesinin F/K oranı -0,71.

Adverum Biotechnologies KUV 361,15 dir.

Adverum Biotechnologies için AlleAktien Kalite Skoru 4/10'dur.

beklenen Adverum Biotechnologies cirosu 209.100,00 USD dir.

beklenen Adverum Biotechnologies karı -105,99 Milyon. USD olarak gerçekleşmiştir.

Adverum Biotechnologies Inc is an emerging biotechnology company that focuses on the development of gene therapies for rare diseases. The company was founded in 2006 and is headquartered in Menlo Park, California. Adverum Biotechnologies Inc operates in three divisions: research and development, manufacturing, and commercialization. The research and development division focuses on the development of gene therapy products based on adeno-associated virus (AAV) technology. These products aim to treat rare diseases caused by genetic defects. The manufacturing division is responsible for the production of gene therapy products in commercial quantities. The company has its own production facility operating under Good Manufacturing Practices (GMP) to ensure the highest quality and safety. The commercialization division is responsible for getting the gene therapy products to patients. Adverum Biotechnologies Inc works closely with regulatory authorities, physicians, and healthcare systems to ensure that the products are accessible and affordable. Adverum Biotechnologies Inc's flagship product is ADVM-043, which is currently in clinical trials for the treatment of hemophilia. Hemophilia is a rare blood disorder caused by a deficiency in blood clotting factors. ADVM-043 aims to introduce a functioning blood clotting factor into the patient's body to alleviate the symptoms of the disease. Adverum Biotechnologies Inc also has a pipeline of gene therapy products in the development phase targeting other rare diseases. These include diseases such as Alpha-1 Antitrypsin Deficiency, Retinitis Pigmentosa, and Wilson Disease. Adverum Biotechnologies Inc's business model is based on the development and commercialization of gene therapy products for rare diseases. The company focuses on niche markets where there is an unmet medical need. Thanks to AAV technology, Adverum Biotechnologies Inc is able to develop and manufacture innovative therapies that meet high-quality standards. The company has formed strategic partnerships with other companies in the biotechnology industry to advance its research and development. These include companies like Regeneron Pharmaceuticals and Editas Medicine. Overall, Adverum Biotechnologies Inc is a promising company in the biotechnology industry that focuses on the development of gene therapy products for rare diseases. With a strong team of scientists and executives, as well as a solid pipeline of gene therapy products, the company has all the prerequisites to succeed in the future.

Adverum Biotechnologies, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Adverum Biotechnologies için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Adverum Biotechnologies şirketinin ISIN kodu US00773U1088’dir.

Adverum Biotechnologies 'nin WKN'si A2AJW8 'dir.

Adverum Biotechnologies için Ticker ADVM’dir.

Son 12 ay içerisinde Adverum Biotechnologies, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Adverum Biotechnologies, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Adverum Biotechnologies şirketinin mevcut temettü verimi .

Adverum Biotechnologies dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Adverum Biotechnologies, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Adverum Biotechnologies, 'Sağlık' sektörüne atanmıştır.

Son Adverum Biotechnologies tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 21.09.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 21.09.2024 olarak gerçekleşti.

2023 yılında Adverum Biotechnologies tarafından 0 USD olarak temettüler dağıtıldı.

Adverum Biotechnologies hisselerinin temettüleri USD olarak dağıtılır.